Cargando…
Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program
To provide safe recombinant adeno-associated viruses (rAAV) to patients, scalable manufacturing processes are required. However, these processes may introduce impurities that impact the performance and quality of the final drug product. Empty rAAV capsids are product-related impurities. Regulatory g...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125404/ https://www.ncbi.nlm.nih.gov/pubmed/36927085 http://dx.doi.org/10.1089/hum.2022.218 |
_version_ | 1785030014033461248 |
---|---|
author | Troxell, Bryan Tsai, I-Wei Shah, Kinjal Knuckles, Christopher I. Shelton, Sarah Lindsey, Kate Cardenas, Selene M. Barbosa Roberts, Taylor |
author_facet | Troxell, Bryan Tsai, I-Wei Shah, Kinjal Knuckles, Christopher I. Shelton, Sarah Lindsey, Kate Cardenas, Selene M. Barbosa Roberts, Taylor |
author_sort | Troxell, Bryan |
collection | PubMed |
description | To provide safe recombinant adeno-associated viruses (rAAV) to patients, scalable manufacturing processes are required. However, these processes may introduce impurities that impact the performance and quality of the final drug product. Empty rAAV capsids are product-related impurities. Regulatory guidance requires that accurate analytical methods be implemented early in product development to measure the level of empty capsids. A process confirmation vector, produced from 200 L production, was used to develop and optimize a size exclusion chromatography with UV and multiangle light scattering (SEC-MALS) method. Vector produced from a 500 L production was used to assess the full-to-empty ratio using the following analytical methods: sedimentation velocity analytical ultracentrifugation (SV-AUC), droplet digital PCR (ddPCR) with capsid enzyme-linked immunosorbent assay (ELISA), bulk absorbance at 260/280 nm, cryogenic electron microscopy, and SEC-MALS. This test article was used for a 30-day, non-Good Laboratory Practices animal study that assessed biodistribution of the product (STRX-330). SEC-MALS outperformed the other methods and correlated well with SV-AUC values of full-to-empty particles. In addition, SEC-MALS agreed with ddPCR and ELISA measurements for vector genomes/mL and capsid particles/mL, respectively. SEC-MALS was linear, accurate, and precise while achieving chromatography quality control (QC) recommendations. Compared to other stability-indicating assays, SEC-MALS performed similarly to ddPCR, capsid ELISA, and infectivity assays in accelerated stress studies. In response to alkaline, but not acidic stress, SEC-MALS indicated distinct changes in the DNA content of the monomer Adeno-associated viruses (AAV) peak for STRX-330, which was supported by ddPCR data. Conversely, acidic treatment resulted in more aggregated vector, but did not impact the DNA content. This work indicates that SEC-MALS is a valuable analytical tool in the analytical development and QC testing of AAV. In addition, this work suggests that SEC-MALS can provide fundamental understanding of AAV in response to environmental stress. This may impact steps of the manufacturing process to minimize conditions that reduce performance. |
format | Online Article Text |
id | pubmed-10125404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-101254042023-04-25 Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program Troxell, Bryan Tsai, I-Wei Shah, Kinjal Knuckles, Christopher I. Shelton, Sarah Lindsey, Kate Cardenas, Selene M. Barbosa Roberts, Taylor Hum Gene Ther Methods To provide safe recombinant adeno-associated viruses (rAAV) to patients, scalable manufacturing processes are required. However, these processes may introduce impurities that impact the performance and quality of the final drug product. Empty rAAV capsids are product-related impurities. Regulatory guidance requires that accurate analytical methods be implemented early in product development to measure the level of empty capsids. A process confirmation vector, produced from 200 L production, was used to develop and optimize a size exclusion chromatography with UV and multiangle light scattering (SEC-MALS) method. Vector produced from a 500 L production was used to assess the full-to-empty ratio using the following analytical methods: sedimentation velocity analytical ultracentrifugation (SV-AUC), droplet digital PCR (ddPCR) with capsid enzyme-linked immunosorbent assay (ELISA), bulk absorbance at 260/280 nm, cryogenic electron microscopy, and SEC-MALS. This test article was used for a 30-day, non-Good Laboratory Practices animal study that assessed biodistribution of the product (STRX-330). SEC-MALS outperformed the other methods and correlated well with SV-AUC values of full-to-empty particles. In addition, SEC-MALS agreed with ddPCR and ELISA measurements for vector genomes/mL and capsid particles/mL, respectively. SEC-MALS was linear, accurate, and precise while achieving chromatography quality control (QC) recommendations. Compared to other stability-indicating assays, SEC-MALS performed similarly to ddPCR, capsid ELISA, and infectivity assays in accelerated stress studies. In response to alkaline, but not acidic stress, SEC-MALS indicated distinct changes in the DNA content of the monomer Adeno-associated viruses (AAV) peak for STRX-330, which was supported by ddPCR data. Conversely, acidic treatment resulted in more aggregated vector, but did not impact the DNA content. This work indicates that SEC-MALS is a valuable analytical tool in the analytical development and QC testing of AAV. In addition, this work suggests that SEC-MALS can provide fundamental understanding of AAV in response to environmental stress. This may impact steps of the manufacturing process to minimize conditions that reduce performance. Mary Ann Liebert, Inc., publishers 2023-04-01 2023-04-17 /pmc/articles/PMC10125404/ /pubmed/36927085 http://dx.doi.org/10.1089/hum.2022.218 Text en © Bryan Troxell et al. 2023; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Methods Troxell, Bryan Tsai, I-Wei Shah, Kinjal Knuckles, Christopher I. Shelton, Sarah Lindsey, Kate Cardenas, Selene M. Barbosa Roberts, Taylor Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program |
title | Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program |
title_full | Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program |
title_fullStr | Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program |
title_full_unstemmed | Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program |
title_short | Application of Size Exclusion Chromatography with Multiangle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program |
title_sort | application of size exclusion chromatography with multiangle light scattering in the analytical development of a preclinical stage gene therapy program |
topic | Methods |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125404/ https://www.ncbi.nlm.nih.gov/pubmed/36927085 http://dx.doi.org/10.1089/hum.2022.218 |
work_keys_str_mv | AT troxellbryan applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram AT tsaiiwei applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram AT shahkinjal applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram AT knuckleschristopheri applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram AT sheltonsarah applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram AT lindseykate applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram AT cardenasselenembarbosa applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram AT robertstaylor applicationofsizeexclusionchromatographywithmultianglelightscatteringintheanalyticaldevelopmentofapreclinicalstagegenetherapyprogram |